martes, 20 de marzo de 2018

Sandoz / Novartis y la marijuana (no "combustible")...

.


TORONTO — Licensed medical marijuana producer Tilray Inc. has formed an exclusive alliance with Sandoz Canada, in what it says is the first collaboration between a cannabis producer and a local affiliate of so-called Big Pharma.

Tilray, headquartered in Toronto with production facilities in British Columbia, has signed a binding letter of intent with the Quebec-based affiliate of Sandoz International GmbH, part of global healthcare company Novartis.

As part of the agreement announced Monday, Tilray will become the exclusive collaborator with Sandoz Canada on cannabis-based medical products which are non-smokable or non-combustible such as gel caps and sprays for the domestic market.

Subject to future regulatory changes, the aim is to distribute on a wholesale level these co-branded products to Canadian hospitals and pharmacies, said Tilray’s chief executive officer Brendan Kennedy.

There is still much skepticism towards the medical marijuana industry, and this collaboration with a recognized pharmaceutical company will help alleviate that, he said. 


 
Ver:
How Canada's Tilray is boosting the medical marijuana industry in Australia

As well, patients and physicians may feel more comfortable with cannabis-based products in forms such as pills and creams that are familiar.

That was part of the opportunity we saw… To distribute Tilray products that have the Sandoz logo that pharmacists, physicians and patients are used to seeing in their pharmaceutical packages. I think that will give physicians confidence and trust in our brand and our product,” he said in an interview.


Ver:

A Novartis también le gusta el cannabis / Sativex


This agreement is the latest example of widening acceptance of cannabis as medicine, as Canada moves to legalize marijuana for recreational use later this year.

(Más)



Ver



Ver también:

Mobile pot bus is rolling into Burnaby


Publicar un comentario